- Markets
- Healthcare
- HEMORGANIC
HEMORGANIC
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Hemo Organic Says Avinashsingh Birendrasingh Rajput Did Not Provide Their Consent To Act As CFO
March 11 (Reuters) - Hemo Organic Ltd HEMO.BO:
HEMO ORGANIC LTD - AVINASHSINGH BIRENDRASINGH RAJPUT DID NOT PROVIDE THEIR CONSENT TO ACT AS CFO
Source text for Eikon: ID:nBSE8jHhFg
Further company coverage: HEMO.BO
(([email protected];))
March 11 (Reuters) - Hemo Organic Ltd HEMO.BO:
HEMO ORGANIC LTD - AVINASHSINGH BIRENDRASINGH RAJPUT DID NOT PROVIDE THEIR CONSENT TO ACT AS CFO
Source text for Eikon: ID:nBSE8jHhFg
Further company coverage: HEMO.BO
(([email protected];))
Hemo Organic Appointed Avinashsingh Birendrasingh Rajput As Chief Financial Officer
Nov 8 (Reuters) - Hemo Organic Ltd HEMO.BO:
APPOINTED AVINASHSINGH BIRENDRASINGH RAJPUT AS CHIEF FINANCIAL OFFICER
MRUGESH PATEL RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE2kTgRY
Further company coverage: HEMO.BO
(([email protected];))
Nov 8 (Reuters) - Hemo Organic Ltd HEMO.BO:
APPOINTED AVINASHSINGH BIRENDRASINGH RAJPUT AS CHIEF FINANCIAL OFFICER
MRUGESH PATEL RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE2kTgRY
Further company coverage: HEMO.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Hemo Organic do?
Dinesh Allorga Ltd specializes in the production and sale of ayurvedic medicines and chemicals.
Who are the competitors of Hemo Organic?
Hemo Organic major competitors are Raymed Labs, Zyden Gentec, Ganga Pharma., Shamrock Indl. Co, MPS Pharmaa, Adline Chem Lab, Fabino Enterprises. Market Cap of Hemo Organic is ₹3 Crs. While the median market cap of its peers are ₹6 Crs.
Is Hemo Organic financially stable compared to its competitors?
Hemo Organic seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Hemo Organic pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Hemo Organic latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Hemo Organic allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Hemo Organic balance sheet?
Hemo Organic balance sheet is weak and might have solvency issues
Is the profitablity of Hemo Organic improving?
The profit is oscillating. The profit of Hemo Organic is -₹0.26 Crs for Mar 2024, -₹0.05 Crs for Mar 2023 and -₹0.06 Crs for Mar 2022
Is the debt of Hemo Organic increasing or decreasing?
Yes, The debt of Hemo Organic is increasing. Latest debt of Hemo Organic is ₹1.24 Crs as of Sep-24. This is greater than Mar-24 when it was ₹1 Crs.
Is Hemo Organic stock expensive?
Hemo Organic is not expensive. Latest PE of Hemo Organic is 0.0, while 3 year average PE is 6.9. Also latest EV/EBITDA of Hemo Organic is 0.0 while 3yr average is 3.16.
Has the share price of Hemo Organic grown faster than its competition?
Hemo Organic has given lower returns compared to its competitors. Hemo Organic has grown at ~-43.52% over the last 3yrs while peers have grown at a median rate of 14.61%
Is the promoter bullish about Hemo Organic?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Hemo Organic is 16.85% and last quarter promoter holding is 16.85%.
Are mutual funds buying/selling Hemo Organic?
There is Insufficient data to gauge this.